The present disclosure relates generally to a protocol to treat or prevent diseases or conditions associated with pathological forms of amyloid beta (Aβ), including Alzheimers disease. Enabled herein is a reagent for use in the treatment and prophylaxis of Aβ-associated pathological conditions.
